Shared on30 Aug 25Fair value Increased 14%
The higher analyst price target for NeoGenomics reflects an expansion in its future P/E multiple despite stable revenue growth forecasts, resulting in a revised fair value of $9.78. What's in the News U.S. District Court invalidated certain Natera patents asserted against NeoGenomics’ RaDaR v1.1 test, but the decision does not affect the '035 patent that previously led to a permanent injunction on RaDaR v1.0. NeoGenomics launched NEO PanTracer LBx, a blood-based comprehensive genomic profiling (CGP) test targeting the expanding liquid biopsy market and enhancing its pan-solid tumor CGP portfolio.
Shared on01 Aug 25Fair value Decreased 22%
The notable downward revision in NeoGenomics’ analyst price target reflects reduced revenue growth forecasts and a lower forward P/E, resulting in a new fair value estimate of $8.72. What's in the News Launched NEO PanTracer LBx, a blood-based comprehensive genomic profiling test for noninvasive therapy selection and monitoring, expanding presence in the $3-5 billion liquid biopsy market.
Shared on17 Apr 25Fair value Decreased 3.85%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 1.64%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Increased 68%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.